High-Dose Eylea’s Improved Durability Could Protect Regeneron’s Market Share
As Roche’s Vabysmo Mounts Threat
The US firm’s high-dose reformulation of Eylea reduced dosing burden for patients with DME and wet AMD in two pivotal studies and could match Roche’s rival drug.
